A comparison of medication adherence/persistence for asthma and chronic obstructive pulmonary disease in the United Kingdom

Summary Aim To describe and compare adherence and persistence with maintenance therapies in patients with asthma or chronic obstructive pulmonary disease (COPD) in the United Kingdom (UK). Methods A retrospective prescribing database cohort was obtained from 44 general practitioner surgeries in Nati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of clinical practice (Esher) 2014-10, Vol.68 (10), p.1200-1208
Hauptverfasser: Covvey, J. R., Mullen, A. B., Ryan, M., Steinke, D. T., Johnston, B. F., Wood, F. T., Boyter, A. C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Aim To describe and compare adherence and persistence with maintenance therapies in patients with asthma or chronic obstructive pulmonary disease (COPD) in the United Kingdom (UK). Methods A retrospective prescribing database cohort was obtained from 44 general practitioner surgeries in National Health Service Forth Valley Scotland. Patients with physician‐diagnosed asthma or COPD who received maintenance therapy between January 2008 and December 2009 were included. Five classes of therapy were assessed: inhaled corticosteroids, long‐acting beta‐agonists, combination therapy inhalers, theophyllines and long‐acting muscarinic antagonists. Adherence was calculated using the medication possession ratio (MPR) and persistence was determined using Kaplan–Meier survival analysis for the time to discontinuation (TTD) over 1 year. Two step‐wise logistic regressions were performed to assess the contribution of diagnosis to adherence/persistence. Results A total of 13,322 patients were included in the analysis: 10,521 patients with asthma and 2801 patients with COPD. 25.2% of medication episodes for asthma and 45.6% of medication episodes for COPD were classified as having an adequate medication supply (MPR of 80–120%). The overall median TTD was 92 days (IQR, interquartile range: 50–186 days) for patients with asthma and 116 days (IQR: 58–259 days, comparison p 
ISSN:1368-5031
1742-1241
DOI:10.1111/ijcp.12451